Abstract: The present invention broadly relates to a process for preparing products comprising active components, and in particular biological materials, wherein the active components are stabilised. The invention further relates to compositions comprising the products, and in particular compositions comprising therapeutic biological materials.

Abstract: In one aspect, there is provided a method for preparing a biocompatible coated substrate. The method generally includes: depositing nucleation amorphous calcium phosphate sites on at least a portion of an outer surface of a substrate by: exposing at least the portion of the outer surface to a mixture having a favorable Ca/P molar ratio, and irradiating with microwave energy; and, stabilizing the deposited nucleation amorphous calcium phosphate sites on the portion of the outer surface. In another aspect, there is provided herein a method for preparing a biocompatible coated substrate.

Abstract: Disclosed herein are compositions comprising an NSAID such as meloxicam in combination with a cyclodextrin and/or a carbonate or a bicarbonate. These compositions may be orally administered, for example, to improve the bioavailability or pharmacokinetics of the NSAID for the treatment of conditions such as pain.

Abstract: A method for determining and graphically marking a position within a lumen of the body of a patient indicative of occlusion includes providing a user interface, using a processor, configured to allow a user to select an occlusion percentage threshold, determining, using the processor, a percentage of occlusion in the lumen, comparing, using the processor, the determined percentage of occlusion with the selected occlusion percentage threshold and identifying a region of the lumen that is occluded more than the selected occlusion percentage threshold, and designating, using the processor, the identified region on an image of the lumen with at least one mark.

Abstract: A malleable demineralized bone composition consists of cortical bone made from a first portion and a second portion. The first portion of cortical bone is made from cut pieces freeze dried then ground into particles and demineralized then freeze-dried. The second portion of cortical bone is shaved into shavings. The shavings are long thin strips subjected to freeze-drying. The freeze-dried shavings are ground and demineralized and then freeze-dried. A volume of the second portion is placed in a solution of sterile water to create a mixture, the water volume being twice the second portion, the mixture is autoclaved under heat and pressure to form a gelatin, and the first portion is mixed with the gelatin to form a malleable putty or paste.

Abstract: The present invention discloses a freezing-illumination method for preparing porous gels, comprising the steps of: (a) synthesizing the gels containing dynamic exchangeable bonds; (b) illuminating the gels under frozen state by certain wavelength light source; (c) elevating the temperature and melt the ice crystals within the gels to get the porous structure. The dynamic exchangeable bonds existing in the gels include double/multi-sulfur bond, hydrazine bond, boronic ester bond. Catalyst is also included in the gel composition to activate the bond exchange reactions under illumination. This new method for preparing porous gels is easy to operate and suitable for most kinds of gels. Meanwhile, it can spatially control the pore structure within the gels by local illumination.

Abstract: An injectable intramuscular depot composition suitable for forming an in situ solid implant in a body, comprising a drug which is paliperidone and/or its pharmaceutical acceptable salts in any combination thereof, a biocompatible copolymer based on lactic and glycolic acid having a monomer ratio of lactic to glycolic acid of about 50:50 and DMSO as solvent, wherein the composition releases the drug with an immediate onset of action and continuously for at least 8 weeks and wherein the composition has a pharmacokinetic profile in vivo suitable for the formulation to be administered each 8 weeks or even longer periods.

Abstract: Nanofibrous hydrogel microarray systems that act as facile, high throughput platforms for in vitro drug discovery and investigation and screening of combinatorial effects of physical and biochemical cues on maturation and differentiation of mammalian cells.

Abstract: A biocompatible, electrically conductive biomaterial capable of earn carrying the electrical potential of a cardiac impulse and comprising (1) a conductive polymer such as polyaniline, polypyrrole or polythiophene, and (ii) a biocompatible component such as a polysaccharide, a protein, or a polypeptide, in particular chitosan or gelatin, is described. The material can take the form of a hydrogel, membrane, sheet or mesh. It can be used to restore or improve electrical impulse propagation across damaged tissue or scar region of the myocardium, in particular in the ti treatment of myocardial infarction and arrhythmia.

Abstract: A nanowire energy storage device such as a nanowire battery or a capacitor having a cathode comprising a plurality of nanowires and an anode comprising a plurality of nanowires interlaced with the plurality of nanowires of the cathode, and embedded in a PMMA gel electrolyte.

Abstract: The present invention is directed to an injectable intramuscular depot composition suitable for forming an in situ solid implant in a body, comprising a drug which is risperidone and/or paliperidone or any pharmaceutically acceptable salt thereof in any combination, a biocompatible copolymer based on lactic and glycolic acid having a monomer ratio of lactic to glycolic acid of about 50:50 and a DMSO solvent, wherein the composition releases the drug with an immediate onset of action and continuously for at least 4 weeks and wherein the composition has a pharmacokinetic profile in vivo that makes it suitable to be administered each 4 weeks or even longer periods.

Abstract: An osteoinductive composition, corresponding osteoimplants, and methods for making the osteoinductive composition are disclosed. The osteoinductive composition comprises osteoinductive factors, such as may be extracted from demineralized bone, and a carrier. The osteoinductive composition is prepared by providing demineralized bone, extracting osteoinductive factors from the demineralized bone, and adding the extracted osteoinductive factors to a carrier. Further additives such as bioactive agents may be added to the osteoinductive composition. The carrier and osteoinductive factors may form an osteogenic osteoimplant. The osteoimplant, when implanted in a mammalian body, can induce at the locus of the implant the full developmental cascade of endochondral bone formation including vascularization, mineralization, and bone marrow differentiation. Also, in some embodiments, the osteoinductive composition can be used as a delivery device to administer bioactive agents.

Abstract: A system and method for automatically calculating an accurate recommended dosage for hormone replacement therapy and automating the life cycle of a patient's treatment over time. The system and method can automatically acquire relevant patient parameters and apply a consistent formulaic approach to help reduce incorrect dosage determinations. A pellet insertion size may be determined and documented based on a calculated dosage, and an insertion side and lot numbers may be tracked and managed. In addition, corresponding revenues may be tracked and profitability may be reported for hormone replacement therapy practices.

Abstract: The present invention relates to a preparation method for core-shell structured fibrous scaffolds, and more specifically to preparing a core part composition and a shell part composition that each have different constitutions by adding calcium phosphate cement and a protein, drug of combination thereof to alginate solution, and then inserting the above core part composition and shell part composition to internal and external nozzle of concentric nozzle respectively to inject into calcium ion aqueous solution and thereby hardening them, thus preparing core-shell structured rapidly setting Alg/?-TCP scaffolds capable of controllably releasing a protein or drug.

Abstract: Sub-100 micron multimodal nanoparticles have four main components: 1) a target element (peptides, lipids, antibodies, small molecules, etc.) that can selectively bind to cells, tissues, or organs of the body; 2) a diagnostic agent such as a fluorophore or NMR contrast agent that allows visualization of nanoparticles at the site of delivery and/or a therapeutic or prophylactic agent; 3) an outside “stealth” layer that allows the particles to evade recognition by immune system components and increase particle circulation half-life; and 4) a biodegradable polymeric material, forming an inner core which can carry therapeutics and release the payloads at a sustained rate after systemic, intraperitoneal, or mucosal administration. These particles possess excellent stability, high loading efficiency, multiple agent encapsulation, targeting and imaging. They are targeted to sites of, or associated with, inflammation caused by a disease, disorder; trauma, chemotherapy or radiation.

Abstract: The present invention provides compositions and formulations of micronized Wharton's jelly having a controlled viscosity such that when delivered to the injured region of a subject, it remains substantially localized with little or no migration out of the injured region for the repair and/or regeneration thereof. Micronized Wharton's Jelly can be suspended in a pharmaceutically acceptable aqueous carrier, such as saline, sterile water, or any suitable buffer, to form a suspension or a gelatinous gel composition, or it can be in the form of a paste, suitable for delivery into the space adjacent the articular surface cartilage injured region of a subject. The micronized Wharton's jelly when employed at sufficient concentrations can be hydrated into a gel or paste and administered topically, or it can be injected into the body through the use of a needle and syringe.

Abstract: A biocompatible curable composition and a method of detecting a border of a tumor, a tissue of interest, or both including injecting the biocompatible curable composition and contacting the border of a tumor or a tissue, the biocompatible curable composition crosslinks to form a three-dimensional cured nanocomposite, and imaging the three-dimensional (3D) cured nanocomposite, and imaging the 3D cured nanocomposite by at least one of MRI, CT, ultrasound, and X-ray, to detect the border of the tumor or the tissue of interest or track tumor motion during radiotherapy treatment. The biocompatible curable composition comprising an organic polymer having a hydrolysable functional group, a metallic nanoparticle, and a polar or a non-polar solvent. A brachytherapy strand consisting of a biocompatible curable composition and a radio-isotope seed. The biocompatible curable composition is shaped into an elongated cylinder and forms a 3D cured nanocomposite with a radio-isotope seed embedded.

Abstract: A solution for forming a marker or filler mass for an intracorporeal site. The solution contains a polar, water soluble non-aqueous solvent such as dimethyl sulfoxide and a bioabsorbable, essentially water insoluble polymer such as polylactic acid, or copolymers of lactic acid and glycolic acid. The solution may be delivered to the biopsy site by a suitable syringe and delivery tube. The delivery tube is preferably provided with a releasable radiopaque element on the distal tip which can be released within the polymeric marker mass formed in the biopsy cavity.

Abstract: The present invention relates to compositions and methods for treating diseases and disorders including cancer and various other angiogenic-dependent diseases, vascular malfunctions, arteriovenous malformations (AVM), hemorrhagic processes and treatment of pain, in particular tumor-related pain by drug delivery and/or therapeutic embolization using microspheres. More particularly the invention relates to microspheres containing non-ionic contrast agents, to compositions comprising these microspheres, as well as methods for preparing and using such compositions for embolization therapy. The invention further relates to compositions and methods using detectable microspheres for targeted drug delivery, irrespective of whether embolization is also needed.

Abstract: The invention relates to compositions for synchronizing the time of insemination in an animal. More particularly, the invention relates to a process for manufacturing and stabilizing GnRH-containing compositions for use in synchronizing the time of insemination in an animal.

Abstract: Adjuncts for surgical devices including agonists and antagonists are provided. In general, an implantable adjunct can have two or more medicants releasably disposed therein that are each releasable from the adjunct. At least one of the medicants can include an agonist configured to encourage a physiological response, and at least one of the medicants can include an antagonist configured to discourage the physiological response encouraged by the agonist. The physiological response can include an aspect of wound healing such that the aspect of wound healing may be both encouraged by and discouraged by the adjunct. The adjunct having one or more agonists and one or more antagonists releasably disposed therein can be configured to be applied to tissue by a surgical stapler in conjunction with staples.

Abstract: Biodegradable implants comprising dopamine modulating compounds are described.

Abstract: This document discusses, among other things, a system for translocating a multilayer patch. The system includes a support structure having a contact surface for bonding to the patch. The support structure has a shape configured to support the patch following separation of the patch from a surrounding tissue.

Abstract: The object of the present invention is a method for obtaining an injectable hydrogel based on hyaluronic acid containing lidocaine hydrochloride and an alkaline agent, sterilized with heat, having hyaluronic acid concentration and flow properties, equivalent to those of the corresponding hydrogel based on hyaluronic acid not containing any lidocaine hydrochloride. The present invention also relates to various uses of the aforementioned hydrogel.

Abstract: Described herein is a porous copolymer membrane composed of poly(styrene sulfonate)-block-polyethylene-block-poly(styrenesulfonate) for use in the absorption of doxorubicin, and a chemofiltration catheter incorporating the membrane for use in transarterial chemoembolization.

Abstract: This invention is a prosthetic device generally placed on the outside surface of the vessel or graft which then elutes antiproliferative drugs or agents from a drug-eluting matrix material. Methods of perivascular antiproliferative drug administration also are disclosed.

Abstract: Embodiments of the disclosure relate to a biosample plate that includes a memory component for storing biosample identification and analysis data, and a wireless communication interface for transferring the data to and from the biosample plate. In one embodiment, the biosample plate comprises a base for receiving a biosample, a memory component coupled to the base for storing identification and analysis information related to the biosample, and a wireless communication interface coupled to the memory component for transferring the information to and from the memory component. The wireless communication interface may include an electromagnetic device.

Abstract: A method for delivering drugs into cystic fluid, the method comprising injecting a drug delivery system (DDS) into a cystic fluid space at an injection site, the DDS comprising at least one therapeutic agent encapsulated in biodegradable polymers, applying ultrasonic energy proximal to the injection site, and controlling the at least one of buoyancy, delivery location, mixing, and dispersion of the DDS to a targeted area using the ultrasonic energy.

Abstract: Provided herein is a placental product comprising an immunocompatible chorionic membrane. Such placental products can be cryopreserved and contain viable therapeutic cells after thawing. The placental product of the present invention is useful in treating a patient with a tissue injury (e.g. wound or burn) by applying the placental product to the injury. Similar application is useful with ligament and tendon repair and for engraftment procedures such as bone engraftment.

Abstract: The present invention relates to a process for preparing a porous layer of biocompatible polymer, having a uniform density and porosity, comprising the following steps: a) a quantity Qp of solution of the said polymer, having a viscosity Vp, is poured into a mold in order to form a first sublayer, the surface of the first sublayer being left to the open air; b) a quantity Qs of solvent, having a viscosity Vs, lower than Vp, is spread uniformly over the surface of the first sublayer so as to form a second sublayer; c) the first and second sublayers are subjected to a step of lyophilization, in which the said polymer is a polysaccharide chosen from hyaluronic acid, alginic acid and chitosan, salts thereof and mixtures thereof.

Abstract: Blood purification device having an extracorporeal blood circuit with a blood inflow and outflow to and from a dialysis unit, wherein the dialysis unit comprises a dialysis solution inflow and a dialysate outflow, characterized by a control loop for control of the acid-base equilibrium of the blood, wherein bicarbonate is supplied to the blood using an aqueous bicarbonate-containing solution, wherein a measuring means for measuring a blood buffer parameter is associated with the control loop, wherein the blood buffer parameter is selected from one of bicarbonate concentration and CO2 partial pressure, and wherein a signal corresponding to the measured value of the blood buffer parameter can be supplied to a closed-loop control apparatus, which regulates the value of the blood buffer parameter by the supply of bicarbonate, and at least one pH-measuring means, wherein a signal corresponding to the pH value can be supplied to an alarm apparatus.

Abstract: This invention relates a controlled release delivery composition for an otorhinolaryngology and otorhinolaryngology-associated pathology, conditions, indications or their combination, Head and Neck associated pathology conditions, indications or their combination, or their combination, using a chitosan-glycerophosphate (CGP) hydrogel and an agent or a bio-materials. Additionally, provided methods of treating an otorhinolaryngology and otorhinolaryngology-associated pathology, conditions, indications or their combination, Head and Neck associated pathology conditions, indications or their combination, or their combination.

Abstract: The present invention is directed to treatment methods for a disease or condition, in a subject in need of such treatment, that provide alternatives to treatment by injection that give, relative to treatment by injection, improved treatment outcomes, 100% treatment compliance, reduced side effects, and rapid establishment and/or termination of substantial steady-state drug delivery. The method typically includes providing continuous delivery of a drug from an implanted osmotic delivery device, wherein substantial steady-state delivery of the drug at therapeutic concentrations is typically achieved within about 7 days or less after implantation of the osmotic delivery device in the subject and the substantial steady-state delivery of the drug from the osmotic delivery device is continuous over a period of at least about 3 months. In one embodiment, the present invention is directed to treatment of type 2 diabetes mellitus using incretin mimetics.

Abstract: The invention relates to methods of preparing a bone matrix solution, a bone matrix implant, and variants thereof. The invention also relates to methods of cell culture using the same. The invention further relates to bone matrix scaffolds comprising one or more bone matrix nanofibers, methods of preparing, and methods of use thereof. The invention also relates to methods of culturing cells and promoting differentiation of stem cells using the same.

Abstract: A process for the preparation of injectable pharmaceutical compositions for the sustained release of somatostatin analogs and compositions prepared according to the process. The process may comprise lyophilizing a mixture of lanreotide acetate and acetic acid to form a lyophilizate and hydrating the lyophilizate, wherein the lyophilization is performed only once.

Abstract: Devices and methods for transplanting cells in a host body are described. The cell comprises a porous scaffold that allows ingrowth of vascular and connective tissues, a plug or plug system configured for placement within the porous scaffold, and a seal configured to enclose a proximal opening in the porous scaffold. The device may further comprise a cell delivery device for delivering cells into the porous scaffold. The method of cell transplantation comprises a two step process. The device is incubated in the host body to form a vascularized collagen matrix around a plug positioned within the porous scaffold. The plug is then retracted from the porous scaffold, and cells are delivered into the vascularized space created within the porous scaffold.

Abstract: The present invention implements a set of grooves/ridges created on Ti at the circumferential direction to increase surface area of implant in contact with bone. These grooves/ridges protect nanofiber matrix (NFM) made with Polycaprolactone (PCL) electrospun nanofiber (ENF) and collagen at the groove from physiological loading. Controlled fabrication of a ridge made with titanium nitride (TiN) around the circumference of Ti is provided using a plasma nitride deposition technique. PCL ENF may be deposited along the sub-micrometer grooves using the electrospin setup disclosed. The method provides for fabrication of microgroove on Ti using machining or TiN deposition and filling the microgrooves with the NFM. This method has proven through experimentation to be successful in increasing in vivo mechanical stability and promoting osseointegration on Ti implants. The immobilization of MgO NP and FN with the PCL-CG NFM on microgrooved Ti as provided in the invention optimizes biological performances of Ti.

Abstract: Embodiments of the disclosure relate to a biosample plate that includes a memory component for storing biosample identification and analysis data, and a wireless communication interface for transferring the data to and from the biosample plate. In one embodiment, the biosample plate comprises a base for receiving a biosample, a memory component coupled to the base for storing identification and analysis information related to the biosample, and a wireless communication interface coupled to the memory component for transferring the information to and from the memory component. The wireless communication interface may include an optical device.

Abstract: Disclosed herein are compositions comprising an NSAID such as meloxicam in combination with a cyclodextrin and/or a carbonate or a bicarbonate. These compositions may be orally administered, for example, to improve the bioavailability or pharmacokinetics of the NSAID for the treatment of conditions such as pain.

Abstract: A bone material comprising a coherent mass of cartridge milled and demineralized bone fibers is provided, the coherent mass having no binder disposed in or on the coherent mass. In some embodiments, a bone material comprising a lyophilized coherent mass of cartridge milled and demineralized bone fibers is provided, the lyophilized coherent mass having no binder disposed in or on the coherent mass. In some embodiments, a method of making an implantable bone material is provided, the method comprising drying a coherent mass of cartridge milled and demineralized bone fibers, the coherent mass having no binder disposed in or on the coherent mass.

Abstract: The present disclosure includes joint replacement implants. The joint replacement implant allows for full articulation of the joint, while absorbing impact of the components during normal use that will reduce wear on the implant components and prolong life. The joint replacement implant may include a bone implantable component and a bearing component having an articulation surface that is sized and shaped to substantially mate with at least a portion of the bone implantable component and a damping mechanism that includes a contact member disposed at least primarily inside a cavity; a biasing member biasing the contact member toward an upper aperture of the cavity and means for capturing the contact member within the cavity.

Abstract: Compositions and methods for treating subjects with disorders characterized by hyper-proliferating cells such as tumors and cancers are provided. The compositions comprise agents that are combinations of saposin C (or prosaposin-related polypeptides) and phospholips (or inner leaflet components). This anti-tumor agent is administered in the methods of the invention according to a dosing regimen. Administering an agent of the invention results in a positive therapeutic response in a subject with a tumor.

Abstract: Disclosed herein telomerase inhibitors and controlled-release formulations thereof, the use of telomerase-inhibiting porphyrins, especially metalloporphyrins, in the controlled-release intratumoral implants for the treatment of cancer. Provided herein also specific compositions of metalloporphyrins and poly-(lactic-co-glycolic)-acid copolymers, in various implantable forms, and methods of treatment cancer by administering the implants of the invention, alongside possible co-treatment with brachytherapy radioactive seeds to precipitate Auger effect of the metal atoms contained in the metalloporphyrins.

Abstract: The present invention relates to a system, a method and a filler for measuring a dose of ionizing radiation received by a pre-determined part of the body during radiotherapy while creating a space between the organ to be irradiated and organs to be protected. The invention also relates to uses of such filler. The system comprises an injectable dosimetric filler, which under the influence of ionizing irradiation undergoes measurable physical and/or chemical changes, while preserving its spatial integrity; a detector system for measuring the physical and/or chemical changes within the radiation sensitive filler by sending an energy wave to the radiation sensitive filler and capturing the signal emitted therefrom; and a control unit for processing the signal captured by the detector system and calculating a dose of ionizing radiation previously or simultaneously received by each part of the volume of the radiation sensitive filler on the basis of said signal.

Abstract: Bone implant compositions and methods are provide that have a first surface and a second surface, the first surface and the second surface comprising a demineralized bone matrix and having a plurality of perforations configured to receive demineralized bone; and a third surface of the bone implant comprising cortical bone, the third surface disposed between the first surface and the second surface. The bone implant compositions and methods provided are osteoinductive and allow rapid bone fusion.

Abstract: Pharmaceutical composition made of microparticles for the slow release of an active substance at least during a period covering the 6th month after injection of said composition, said composition comprising a group of microparticles made of a copolymer of the PLGA type which incorporate an active substance in the form of a water insoluble peptide salt; said copolymer furthermore comprising at least 75% of lactic acid and an inherent viscosity between 0.1 and 0.9 dl/g, as measured in chloroform at 25° C. and at a polymer concentration of 0.5 g/dL; said microparticles furthermore having a size distribution defined as follows: —D (v,0.1) is between 10 and 30 micrometers, —D (v,0.5) is between 30 and 70 micrometers, —D (v,0.9) is between 50 and 1 10 micrometers.

Abstract: An implantable prosthetic device for the repair of damaged cartilage including methods of implantation and repair. The prosthetic device is formed from a biocompatible pad having an open structure connected to a textile or non-woven sheet-like anchor. In one embodiment the anchor comprises legs that extend away from a perimeter region of the pad and spaced apart along their respective lengths such that an in unfolded orientation, the longitudinal edges of neighbouring legs are not in contact with one another and a spatial gap is provided between the anchoring legs. The anchor may also be provided in the form of strips to which anchorage sutures or other medical cords may be attached to fixate the device between connective tissue.

Abstract: A particulate composition for stimulating nucleus pulposus regeneration has a particulate composition made of vertebral end-plates having an osseous component wherein the composition is milled, ground or particulized into particles from 10 to 1000 microns in size. At least a part of the composition can be non-demineralized or demineralized or a mixture of demineralized and non-demineralized particles from the vertebral end-plates. Preferably, the non-demineralized part is not subjected to harsh chemical treating. To possibly enhance the release of growth factors and other similar substances from the osseous layer of the end-plate, the material may be treated with hydrochloric acid, ethylene diamine or other demineralizing agents or regimens.

Abstract: The present invention relates to improved hemostatic compositions comprising cellulose-based fibers supplemented with compounds, preparation and use thereof.

Abstract: A method for immobilizing dyes and antimicrobial agents on a polymeric cover or housing for a medical device is disclosed and described. The surface may be that of a catheter, a connector, a drug vial spike, a bag spike, a prosthetic device, an endoscope, a surface of an infusion pump, a key pad, a touch screen or a handle. The surfaces may also be one or more of those associated with a infusion of a medicament or dialysis treatment, such as peritoneal dialysis or hemodialysis, where it is important that the working surface for the dialysis fluid be sterile. These surfaces include connectors for peritoneal dialysis sets or for hemodialysis sets, bag spikes, dialysis catheters, and so forth. A method for determining whether a surface has been sterilized, and a dye useful in so indicating, is also disclosed.